Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Merck’s Welireg won FDA approval for adult patients with von Hippel-Lindau disease who require therapy for associated RCC, central nervous system, and hemangioblastomas.
The U.S. FDA greenlit the combination of Keytruda and Eisai’s Lemvima as a first-line treatment for adult patients with advanced renal cell carcinoma.
It was a busy week for clinical trial announcements. Take a look.
Shares of Autolus were up more than 12% this morning after it forged an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.
Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a “pay-for-delay” scheme that cost the former millions of dollars.
While modern-day science has provided the world with highly effective vaccines to fight the COVID-19 pandemic, researchers have had less luck finding effective treatment options for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Merck’s Keytruda won FDA approval for the treatment of patients with high-risk, early-stage triple-negative breast cancer. The approval marked the 30th for Keytruda.
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
JOBS
IN THE PRESS